Recognition of ErbB Family Dimers by the EGF-like Domain of NRG1alpha and Beta: Implications for Ligand-Based CAR Therapy
Alex Novikov, Alon Naumchik, Rajashri Banerji, Yariv Greenshpan, Kamran Waidha, Baisali Bhattacharya, Moshe Elkabets, Olga Radinsky, Angel Porgador · 2026
Read Recognition of ErbB Family Dimers by the EGF-like Domain of NRG1alpha and Beta: Implications for Ligand-Based CAR Therapy by Alex Novikov, Alon Naumchik, Rajashri Banerji, Yariv Greenshpan, Kamran Waidha, Baisali Bhattacharya, Moshe Elkabets, Olga Radinsky, Angel Porgador (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13466763.txt.
Description
Alex Novikov and colleagues engineer immune cells guided by a natural growth factor fragment to attack cancers driven by the HER receptor family, in a 2026 study. Standard engineered T cell therapy aimed at HER2 alone struggles with safety problems and tumors that shed the target. Their reporter system reads which receptor pairs a tumor actually displays.
The beta form of neuregulin-1 grips this receptor family flexibly, so cells built around it kept working even in models that had lost HER2. In three-dimensional tissue models the approach killed tumors strongly while releasing a calmer mix of inflammatory signals than current clinical designs. Natural killer cell versions were built alongside the T cell ones.
Catalog record
| CREATOR | Alex Novikov, Alon Naumchik, Rajashri Banerji, Yariv Greenshpan, Kamran Waidha, Baisali Bhattacharya, Moshe Elkabets, Olga Radinsky, Angel Porgador |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |